Clinigen Ltd (Clinigen) is a pharmaceutical and services company that provides access to clinical trials, medicines and unlicensed and commercial supplies. The company’s products include dexrazoxane, crisantaspase, amifostine, foscarnet sodium, acetylcysteine, cholecalciferol, folic acid, gabapentin, glycopyrronium bromide, iloprost, and others. It carries out clinical trial services, partnering, IDIS-managed access, clinical supply management, and others. Clinigen's clinical trial services comprise packaging and labeling, direct-to-site delivery, global storage and distribution, ancillary supply sourcing, and controlled drug services. The company serves biotechnology and pharmaceutical companies; and healthcare professionals. It operates in Japan, the US, New Zealand, Australia, Singapore, South Africa, and the UK. Clinigen Group is headquartered in Burton-on-Trent, Staffordshire, the UK.
Headquarters
United Kingdom
Address
Pitcairn House, Crown Square, First Avenue, Burton Upon Trent, England, DE142WW
Website
www.clinigengroup.com
Telephone
44 1283 495010
No of Employees
1,150
Industry
Pharmaceuticals and Healthcare
Revenue (2021)
$671.6M
Clinigen Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Dexrazoxane | Clinical Trial Services | Erwinase |
| Crisantaspase | Global Access | Foscavir |
| Amifostine | IDIS Managed Access | Imukin |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
Competitor Comparison
| Key Parameters | Clinigen Ltd | AstraZeneca Plc | GSK plc | Niox Group Plc | Innaxon Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | Burton Upon Trent | Cambridge | Brentford | Oxford | Tewkesbury |
| State/Province | England | England | England | England | England |
| No. of Employees | 1,150 | 89,900 | 70,212 | 85 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jerome Charton | Chief Executive Officer | Senior Management | 2023 | - |
| Michael Mensa | Chief Financial Officer | Senior Management | 2023 | - |
| Samuel Gordon Herbert | Director | Senior Management | 2023 | 40 |
| Marc Hennebert | Senior Vice President - Business Development | Senior Management | 2023 | - |
| David John Bryant | Director | Senior Management | 2023 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward